Compare HYFM & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYFM | ONCO |
|---|---|---|
| Founded | 1977 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 4.0M |
| IPO Year | 2020 | 2021 |
| Metric | HYFM | ONCO |
|---|---|---|
| Price | $0.89 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.7K | ★ 411.0K |
| Earning Date | 05-12-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $134,252,000.00 | $815,371.00 |
| Revenue This Year | $57.44 | N/A |
| Revenue Next Year | $5.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.79 | $0.09 |
| 52 Week High | $4.78 | $6.73 |
| Indicator | HYFM | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 38.87 | 49.72 |
| Support Level | $0.83 | $0.92 |
| Resistance Level | $1.07 | $1.87 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 24.32 | 20.61 |
Hydrofarm Holdings Group Inc is an independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture (CEA), including grow lights, climate control solutions, grow media, nutrients, and other products. Hydroponics involves growing plants in soilless media, often using artificial lighting in controlled indoor or greenhouse environments. Its products are used to cultivate cannabis, flowers, fruits, vegetables, grains, and herbs, enabling control over key factors such as temperature, humidity, light, nutrients, and pH. Its product portfolio spans lighting, grow media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies. The United States generates maximum revenue.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.